Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher

Ferrari de Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018;359:1537-1542 pubmed publisher

Noguchi T, Ward J, Gubin M, Arthur C, Lee S, Hundal J, et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res. 2017;5:106-117 pubmed publisher

Howland S, Poh C, Rénia L. Activated Brain Endothelial Cells Cross-Present Malaria Antigen. PLoS Pathog. 2015;11:e1004963 pubmed publisher

Kobayashi T, Doff B, Rearden R, Leggatt G, Mattarollo S. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology. 2015;4:e990793 pubmed

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow S, Yong M, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125:2077-89 pubmed publisher

Allard B, Pommey S, Smyth M, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19:5626-35 pubmed publisher

Verbrugge I, Hagekyriakou J, Sharp L, Galli M, West A, McLaughlin N, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012;72:3163-74 pubmed publisher

Ahmed K, Wang L, Munegowda M, Mulligan S, Mulligan S, Gordon J, et al. Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. J Leukoc Biol. 2012;92:289-300 pubmed publisher

Takada K, Jameson S. Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. J Exp Med. 2009;206:2253-69 pubmed publisher